Stryker (SYK) Akcie Kurz
Stryker Kurz
Za posledních 19 let vzrostly tržby Stryker o 8,4 % ročně a dosáhly 25,12 Mld. USD. Zisk na akcii rostl o 8,2 % ročně za posledních 19 let. U Stryker je čistá marže 12,9 % nahoru oproti 11,7 % před několika lety. Při dnešní ceně vychází dividendový výnos zhruba na 1,12 %. Výplatní poměr je kolem 40 % zisku. Dividenda rostla o 15,5 % ročně za posledních 19 let. Konsenzuální 12měsíční cílová cena pro Stryker je 380,00 USD, asi nad cenu o 24,8 %. Z 35 analytiků jich 27 doporučuje nákup — celkový konsenzus je Koupit.
Cena akcie Stryker
Tato data přes Eulerpool API
100 000 požadavků/měs. zdarma · bez karty
Obchodní model Stryker a analýza akcií
Nejčastější otázky týkající se akcie Stryker
The business model of Stryker Corp focuses on providing innovative medical technologies and solutions worldwide. As a leading medical technology company, Stryker Corp specializes in products and services across various segments, including orthopedics, medical and surgical, neurotechnology, and spine. With a strong emphasis on research and development, Stryker Corp strives to deliver advanced and effective healthcare solutions to improve patient outcomes. The company's commitment to innovation, quality, and customer satisfaction has made it a trusted name in the medical industry. Stryker Corp's business model revolves around leveraging its expertise and cutting-edge technologies to meet the evolving needs of healthcare professionals and enhance the lives of patients.
Stryker Corp is primarily active in the healthcare industry.
The main competitors of Stryker Corp in the market are Johnson & Johnson, Medtronic, Zimmer Biomet Holdings, and Boston Scientific.
Stryker Corp is a renowned American medical technology company established in 1941. With over 80 years of experience, Stryker has evolved into a global leader specializing in surgical equipment and orthopedic implants. The company's roots trace back to its founding by Dr. Homer Stryker, an innovative orthopedic surgeon who developed various medical devices. Today, Stryker Corp offers a wide range of products across multiple medical disciplines, including reconstructive devices, neurotechnology, spine systems, and more. The company's commitment to innovation, coupled with strategic acquisitions, has solidified its position as a trusted name in the medical industry.
Stryker Corp has achieved significant milestones throughout its history. A major accomplishment for the company was the development and introduction of the first-ever surgical navigation system, the Navigation System II. This technology revolutionized surgical procedures by providing real-time imaging and guidance to surgeons, improving precision and patient outcomes. Another notable milestone for Stryker Corp was the acquisition of Howmedica, a leading orthopedic company, in 1998. This strategic move further strengthened Stryker Corp's position in the medical technology industry, enhancing its product portfolio and global presence. Over the years, the company has continued to innovate and has been recognized for its advancements in medical devices and solutions.
Stryker Corp is primarily present in various countries and regions worldwide. Some of the key locations include the United States, where the company is headquartered in Kalamazoo, Michigan. Additionally, Stryker has a significant presence in Europe, with operations in countries such as Germany, France, the United Kingdom, Italy, and Switzerland. The company is also active in the Asia-Pacific region, specifically in countries like China, Japan, India, and Australia. With its global reach, Stryker Corp ensures its innovative medical technologies and products are available to healthcare professionals and patients across different parts of the world.
Stryker Corp represents values of innovation, integrity, and excellence in the medical technology industry. The company's corporate philosophy centers around delivering high-quality products and services that improve patient outcomes and enhance healthcare providers' capabilities. By continually investing in research and development, Stryker strives to introduce cutting-edge solutions that address critical healthcare needs and promote sustainable growth. With a commitment to ethical business practices and global collaboration, Stryker focuses on delivering value to its stakeholders, including healthcare professionals, patients, employees, and shareholders. Stryker Corp's dedication to advancing medical technology and improving lives embodies its core values and corporate philosophy.
Analytici aktuálně stanovují průměrnou cílovou cenu 382,61 USD pro akcii Stryker (medián: 380,00 USD), tedy +23,2 % vůči poslední ceně. Konsensus vychází z 35 hodnocení analytiků.
35 analytiků aktuálně hodnotí akcii Stryker: 27 doporučuje koupit, 8 držet a 0 prodat. Pro rok 2026 analytici očekávají u Stryker tržby 27,18 Mld. USD a zisk na akcii 14,95 USD.
Při aktuálním kurzu se akcie Stryker obchoduje za 270,89 EUR (304,40 USD).
Akcie Stryker (SYK) je kótována na 12 burzách, mimo jiné: NYSE (SYK), London (0R2S.L), SIX (Zürich) (SYK.SW), XETRA (SYK.DE), Frankfurt (SYK.F), München (SYK.MU), Stuttgart (SYK.SG), Düsseldorf (SYK.DU).
Stryker Corp is a US-American company that specializes in the manufacturing and sale of medical devices, implantable products, and medical services. The company was founded in 1941 and has since become a leading company in the medical technology industry. Stryker has four business segments, namely Medical Devices, Orthopedics, Medical and Surgical Instruments, and Neurotechnology and Spine Products. In the Medical Devices segment, Stryker offers a wide range of products including endoscopy devices, respiratory devices, patient monitoring devices, neurological monitoring devices, and medical lighting systems. These products are used in hospitals and clinical facilities for patient diagnosis and treatment. In Orthopedics, Stryker is one of the world leaders in implants and instruments for joint surgery. The company offers products for the hip, knee, shoulder, wrist, and other joints. Stryker has also taken a leading role in introducing robotics in surgery in this field. The Mako robot allows for precise implantations, enabling patients to have faster recovery and improved quality of life. The Medical and Surgical Instruments segment includes a wide range of instruments for surgery, including surgical saws, scalpels, forceps, and other instruments for various surgical procedures. These instruments are used by physicians for a variety of surgical interventions. In the Neurotechnology and Spine Products segment, Stryker develops and distributes products for spinal surgery, including implants for intervertebral discs and for stabilization of the cervical and lumbar spine. In addition to selling products, Stryker also offers medical services. This includes consulting and support for the implementation of products and systems in hospitals and medical facilities. Technical support and customer service are also part of the offerings. Stryker's business model is based on its ability to develop and produce innovative and high-quality products for the medical field. The company emphasizes close collaboration with medical professionals to ensure that the offered products meet the requirements of the practice and enable optimal treatment for patients. The company also strives to continuously improve its products and develop new technologies. In particular, the introduction of robotics in surgery offers Stryker significant growth opportunities as it has the potential for higher efficiency, precision, and better treatment outcomes. Overall, Stryker is a leading company in the medical technology industry, specializing in the development of innovative products and the provision of high-quality medical services. The company has a wide range of products in various business segments, including Medical Devices, Orthopedics, Medical and Surgical Instruments, and Neurotechnology and Spine Products. Stryker's business model is based on serving medical professionals with high-quality products and services and developing innovative technologies to achieve even better treatment outcomes for patients.
Tržby očekávané za Stryker činí 27,18 Mld. USD. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.
Zisk očekávané za Stryker činí 5,78 Mld. USD. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.
Poměr ceny k zisku (P/E) Stryker je aktuálně 20,36. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie Stryker.
Poměr ceny k tržbám (P/S) Stryker je aktuálně 4,33. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie Stryker.
Score kvality pro Stryker je 7/10.
ISIN Stryker je US8636671013. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.
WKN Stryker je 864952. WKN (Wertpapierkennnummer) je šestimístný německý identifikační kód cenného papíru.
Ticker Stryker je SYK. Symbol tickeru se používá k obchodování akcií Stryker na burze.
Stryker akcie
Stryker Peer Group
Stryker Ticker
Stryker FIGI
Všechny fundamentální údaje o Stryker v podrobné analýze
Naše analýzy akcií společnosti Stryker zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti Stryker. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy: